About DopaFuse

  • Designed for Parkinson's Disease patients
  • Provides continuous delivery of levodopa
  • May provide more stable drug levels in the blood, potentially reducing "Off" time
  • Uses the OraFuse platform

About OraFuse®

  • OraFuse is SynAgile's proprietary technology for continuous drug delivery in the mouth
  • Can be used for numerous drugs

The OraFuse Technology: A novel, non-invasive method of drug delivery in the mouth

Drug Types

Orally-delivered drugs, including:

Narrow therapeutic index drugs.
Drugs that cannot be formulated for extended release



Buccally-delivered drugs



Topical drugs for the mouth, pharynx, and esophagus

Benefits



More stable plasma drug concentrations.Fewer dose-related side effects.

Allows buccal delivery of drugs requiring frequent or continuous dosing, rather than just drugs requiring episodic dosing.

Allows topical delivery of drugs requiring frequent or continuous dosing to the mouth, pharynx and esophagus.

Founders

SynAgile was founded by highly successful serial inventor-entrepreneurs Adam Heller (CSO) and Ephraim Heller (CEO). The father-son team have over 300 patents (most in use) and a track record which includes the founding of AngioScore (sold for $235 million) and TheraSense (which went public and was later sold for $1.2 billion). Adam Heller is also a coinventor of the first commercialized lithium thionyl chloride battery and a recipient of the US National Medal of Technology and Innovation, the highest technology honor in the United States.

The SynAgile founding team began developing OraFuse after seeing an opportunity to improve patients’ quality of life via a new class of drug delivery devices.

News

A Human Factors Study of the DopaFuse Delivery System

September 22nd, 2019

SynAgile presented its findings of a formative Human Factors study at the 2019 International Congress of Parkinson’s Disease and Movement Disorders. View the poster by clicking below

Read More

Laboratory Performance of the DopaFuse Delivery System

September 22nd, 2019

At the 2019 International Congress of Parkinson’s Disease and Movement Disorders, SynAgile presented its findings of the laboratory performance of the DopaFuse Delivery System. View the poster by clicking below.

Read More

SynAgile Corporation Announces Closing of $10.4M of Financing

August 24th, 2017

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse® technology platform, today announced the closing of a $10.4 million round of equity investment.

Read More
Federal law limits the use of DopaFuse to Investigational Use Only. DopaFuse is not available for sale.